Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A potential blockbuster took a big step closer to market last week as FDA approved Sanofi-Aventis' atrial fibrillation treatment Multaq. The approval represented a comeback for the drug, which was rejected by FDA three years ago over safety concerns. In one of its clinical trials, called Andromeda, Multaq not only failed to benefit patients suffering from severe heart failure, but also increased overall mortality.


Today in Drug/Product Alerts...keeping you current

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09

FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 11/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address